Seeking Alpha

Idenix initiates Phase 2 HCV trial, files patent infringement suits against Gilead

  • Idenix Pharmaceuticals (IDIX) starts patient enrollment in HELIX-2 — that's the DAA HCV combo comprising samatasvir and the JNJ co-developed protease inhibitor and polymerase inhibitor simeprevir and TMC647055.
  • The Phase 2 study will evaluate efficacy, safety and tolerability of the combo in treatment-naïve or relapsed (after interferon and ribavirin) GT1 HCV patients. (PR)
  • In other company news, IDIX has filed two patent infringement lawsuits against Gilead (GILD) tied to methods of treating the HCV using 2'-methyl nucleosides.
  • Here's IDIX: "[The company] is seeking a declaration that GILD's imminent distribution, importation, use, sale or offer to sell drugs containing sofosbuvir, a 2'-methyl nucleoside compound, infringes IDIX's patents." (PR)
Comments (2)
  • rnn
    , contributor
    Comments (203) | Send Message
    Its selling off on the positive article/news.
    2 Dec 2013, 01:13 PM Reply Like
  • MichaelJ8
    , contributor
    Comments (600) | Send Message
    a patent suit.. oh boy. Here we go. Patents are almost worthless in today's age
    2 Dec 2013, 03:01 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: